Shelley Chu serves as Partner at Abingworth Management. Dr. Chu, who has more than 20 years of experience in venture capital, business development and strategic leadership, will source and manage deals across a broad range of therapeutic areas and stages of development, from startups to late-stage investments. Dr. Shelley Chu serves as Board Member of Tizona Therapeutics. Previously Ms. Chu worked at Gilead Sciences where she led business development in oncology, immunotherapy and Hepatitis B, as well as R&D strategy. Dr. Chu holds a Doctorate of Medicine and a PhD in biochemistry and biophysics from the University of California, San Francisco.

Shelley joined Abingworth in 2015 and invests across a broad range of therapeutic areas and stages of development, from start-ups to late-stage. She has over 15 years of operating and investment experience in the biopharmaceutical industry, including most recently Gilead where she led R&D Strategy and Business Development in Oncology, Immunotherapy and Hepatitis B. Previously Shelley invested and co-founded biotechnology companies at Frazier Healthcare Ventures. Earlier in her career she was an investment professional at Flagship Ventures and a management consultant to healthcare and biotech companies at McKinsey.

Shelley holds an MD and PhD in Biochemistry and Biophysics from UCSF, and received her BA in Molecular Biology from Princeton University. She is a first author of publications in Science and other prominent journals and a Co-Chair of the Princeton Alumni School Committee.

Education:
University of San Francisco
University of San Francisco, PhD, Biochemistry & Biophysics

Fund's investment verticals: healthcare, nanotechnology, security, manufacturing, oncology, life sciences, financial services and information technology.